CTRI/2014/02/004409
Completed
Phase 4
A prospective, open label, multicenter clinical trial to assess efficacy and safety of Lipid based Amphotericin B gel 0.1% (Amfy gel®) in patients with moderate to severe vulvovaginal candidiasis after treatment failure with anti-fungal azoles. - NA
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Intas Pharmaceuticals Ltd
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Female patientsâ?? \>\=18 years of age, on an acceptable form of birth control throughout treatment period.
- •2\.The patient willing to give written, signed and dated informed consent to participate in the study before initiating any study related procedure.
- •3\.Clinical diagnosis of symptomatic vulvovaginal candidiasis (score at screening and baseline visit \>\=7 â?? moderately severe cases) confirmed at screening visit by positive KOH wet mount test.
- •4\.History of completing a single standard dose or short course of treatment with anti\-fungal azoles within three months of the current symptomatic episode of VVC.
- •5\.Patient complies with all clinical trial instructions and procedures.
Exclusion Criteria
- •1\.Pregnant or breastfeeding or planning to become pregnant during the treatment period.
- •2\.Diagnosed with disseminated candidiasis or requires systemic antifungal therapy.
- •3\.Has received any topical/systemic antifungal therapy within 7 days prior to visit 2 (baseline).
- •4\.Women suffering from other active infectious cause(s) of vulvovaginitis (e.g., Bacterial vaginosis, Trichomonasvaginalis, Chlamydia trachomatis, Neisseria gonorrhea, symptomatic Herpes Simplex Virus\-1 (HSV\-1\), symptomatic HSV\-2, or symptomatic human papilloma virus).
- •5\.Women with current use of any immunosuppressive drugs, including systemic or topical vaginal corticosteroids.
- •6\.Known case of Hypersensitivity or intolerance (e.g., elevation of liver enzymes) to Amphotericin B.
- •7\.Diagnosed with any concomitant condition that, in the opinion of the investigator, could interfere with the evaluation of efficacy or safety, or would make it unlikely that the patient would complete the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
A study to evaluate the efficacy and safety of vestige spirulina capsules for the immunity in healthy patients.CTRI/2022/09/045585Vestige Marketing Pvt Ltd50
Completed
Phase 4
Amla capsules in improving Overall healthCTRI/2022/09/045192Vestige Marketing Pvt Ltd50
Completed
Phase 4
clinical trail to evaluate efficacy and safety of Vestige Noni capsules in improving Overall health of healthy population.CTRI/2022/09/045314Vestige Marketing Pvt Ltd50
Recruiting
Not Applicable
A Multi-Center, Prospective, Open Label Clinical Trial to Evaluate Impact of Extended Electrocardiographic Monitoring Using MEMO Patch Plus in Patients with Acute Heart FailureDiseases of the circulatory systemKCT0008650Asan Medical Center60
Recruiting
Phase 2
To assess safety and performance of Melangeâ?¢ BRS Sirolimus Eluting BioResorbable Peripheral Scaffold System for Percutaneous Transluminal Renal Angioplasty of atherosclerotic new or restenotic lesion of the renal arteryHealth Condition 1: I701- Atherosclerosis of renal arteryCTRI/2017/10/010120Meril Life Sciences Pvt Ltd